The reduced antigen content diphtheria, tetanus and pertussis (dTpa) vaccine (Boostrix™)
has been shown to induce a strong booster response to all the vaccine components in 4–6 …

Reduced-antigen-content diphtheria–tetanus–acellular-pertussis (dTpa) vaccines are
predominantly recommended for once-in-a-lifetime use. A second dTpa (Boostrix™ …

Background Reduced-antigen-content tetanus, diphtheria, and acellular pertussis (Tdap)
vaccine is recommended in many countries for boosting immunity in adolescents and adults …

A trial to compare the reactogenicity and immunogenicity of a reduced antigen content
diphtheria–tetanus–acellular pertussis (dTpa) vaccine with diphtheria–tetanus–whole-cell …

Introduction: Older children and adults, susceptible to pertussis because of waning
immunity, may serve as a reservoir of infection, leading to severe disease among young …

The need for boosters for tetanus, diphtheria, pertussis, and polio, starting from preschool
age, is related to the waning immune protection conferred by vaccination, the …

Objective: To evaluate immunogenicity and reactogenicity of primary vaccination with
reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) or dTpa-inactivated …

Background In a prospective, randomized pivotal phase III clinical trial, the immunogenicity
and reactogenicity of a tetanus-diphtheria-acellular pertussis vaccine (Tdap) and a tetanus …

Two clinical studies were undertaken to evaluate the immunogenicity of an adult-type dTpa
booster vaccine (Boostrix™ by GlaxoSmithKline Biologicals). Blood samples taken prior to …

BACKGROUND: Older adults, especially those over 65 years, are at risk of more severe
morbidity from diphtheria, tetanus and pertussis and may transmit pertussis to unvaccinated …